Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Radnor Capital Management LLC

Radnor Capital Management LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 358.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,784 shares of the medical research company’s stock after acquiring an additional 18,600 shares during the quarter. Radnor Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,570,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Crewe Advisors LLC purchased a new position in Edwards Lifesciences in the 1st quarter worth about $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the second quarter worth $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences in the second quarter worth $39,000. Versant Capital Management Inc raised its stake in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the second quarter worth $55,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,250 shares of company stock worth $2,746,988. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $66.69 on Wednesday. The stock has a fifty day moving average price of $67.81 and a 200 day moving average price of $77.26. The stock has a market cap of $40.17 billion, a PE ratio of 9.62, a P/E/G ratio of 3.80 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on EW. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Citigroup reduced their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Finally, Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.